Quantcast

Industry news that matters to you.  Learn more

Immunovia Signs Major Autoimmune Biomarker Discovery Collaboration with Linkoping University

Reading time: 2 minutes

Immunovia announced today the signing of a major research collaboration on discovery of diagnostic biomarkers for autoimmune diseases with the Faculty of Medicine and Health Sciences, Linkoping University. The collaboration aims to accelerate the development of a new generation of diagnostic tests based on Immunovia’s leading IMMray™ antibody array platform.

The Linkoping collaboration forms the next step in Immunovia’s autoimmune diseases program and additionally extend the scope of providing solutions to clinical unmet needs. It covers 4 of the major diseases within autoimmunity – Rheumatoid Arthritis (RA) with Prof. Thomas Skogh and Assoc. Prof. Alf Kastbom; Primary Sjogren’s Syndrome with Assoc. Prof. Per Eriksson; Systemic Lupus Erythematosus (SLE) with Assoc. Prof. Christopher Sjowall; Vasculitis with Prof. Marten Segelmark and Assoc. Prof. Per Eriksson. This complements and strengthens the current collaboration with Lund University (see press release published Sept 7, 2017) by providing access to important biobanks of clinically well documented samples and extensive autoimmune diseases expertize.

”We are delighted to sign this collaboration with Linkoping University and to assemble a group of clinicians with such a broad expertise of different autoimmune diseases. There is a major need for differential diagnostics in this area and we believe IMMray™ platform is particularly suited to develop accurate, rapid and reliable patient diagnostics to enable better patient management. Our IMMray™ SLE-d is already showing promising results with differential diagnosis accuracies above 95%, this encouraged us to extend our autoimmune discovery program to the next level, to address the very attractive autoimmune diseases diagnostic market with innovative solutions to currently unmet needs” said Mats Grahn, CEO, Immunovia.

Source: Immunovia